200-word summary
[See videos at the HHS YouTube Channel]
The Advisory Council on Parkinson’s Research, Care, and Services (ACPRCS) is a federal advisory council, a mixed public–federal stakeholder body, and essentially a national policy-and-coordination forum for Parkinson’s disease and related disorders (PDRD).
Created by the 2024 National Plan to End Parkinson’s Act, it advises the HHS Secretary and is helping shape the first integrated federal National Plan addressing prevention, diagnosis, treatment, care, and research. Its membership combines 10 public members with 13 federal representatives.
The August 24, 2026 meeting—the Council’s second—was primarily a listening and agenda-setting meeting, featuring 15 nonprofit organizations, public commenters, development of a federal PDRD inventory, and initial reports from the Research/Regulatory and Care/Services subcommittees.
Across remarkably diverse speakers, several themes converged: substantially greater research investment; earlier and more accurate diagnosis; inclusion of prodromal disease and atypical parkinsonisms; environmental prevention; better clinical-trial infrastructure and biomarkers; and, above all, a severe delivery problem—too few specialists, fragmented multidisciplinary care, inadequate rehabilitation and social-work support, rural disparities, and heavy caregiver burden. The Council increasingly framed research and care around a common “patient journey”, from risk and prodromal disease through advanced illness, with measurable outcomes and accountability rather than a simple list of aspirations.
Detailed Meeting Summary
Purpose and status of the Council
The August 24 meeting showed a Council still early in its development but moving rapidly from statutory mandate toward a working structure. ACPRCS does not itself run Parkinson’s programs or regulate medical care; its central task is to assemble evidence and stakeholder perspectives and translate them into recommendations to HHS and Congress. The National Plan encompasses not only conventional Parkinson disease but related parkinsonisms including MSA, PSP, corticobasal degeneration, and Lewy body dementias, a breadth that repeatedly affected discussion of diagnosis, research methods, care models, and endpoints.
Public engagement was already substantial. NINDS reported almost 400 responses to the formal RFI, from patients, caregivers, professionals, researchers, nonprofits, industry, and people affected by several atypical parkinsonian disorders. The Council emphasized that these responses would help identify priorities for both its recommendations and the National Plan.
Building a federal inventory
A major operational presentation concerned creation of a federal inventory of Parkinson’s-related programs and investments. Importantly, NINDS did not envision this as merely a catalog. The intent is to identify what government is doing well, where duplication or gaps exist, and what should change.
The proposed system would pull standardized information from federal agencies, apply a common PDRD classification framework, use AI/machine learning for initial categorization followed by human validation, and feed the results into a dashboard. Categories include disease mechanisms, diagnosis and monitoring, interventions, epidemiology, care and impact, research infrastructure, common mechanisms across neurodegenerative disease, and workforce/training. Eventually nonprofits may also contribute, permitting comparison of public and philanthropic activity rather than viewing them separately.
Council members strongly supported that broader vision, particularly because it could reveal gaps, duplication, and opportunities for coordinated investment. A draft inventory is planned for spring 2027, with finalization during summer for use in the Council’s fall report.
What the nonprofits told the Council
Although the 15 organizations represented very different constituencies, the striking feature of the presentations was their convergence.
The Michael J. Fox Foundation made the strongest quantitative funding proposal: a long-term federal strategy reaching at least $1.5 billion annually by 2032. Its argument was that scientific opportunity—biomarkers, therapeutic targets, trial infrastructure and precision medicine—has advanced faster than federal investment. APDA likewise sought greater research funding but paired it with development of a longitudinal integrated-care model, including caregivers, and greater attention to nonmotor symptoms and environmental neurotoxicity.
The Parkinson’s Foundation stressed a dual mandate: accelerate cures while improving life now. Its examples highlighted genetic research, environmental prevention, workforce shortages, care navigation, rehabilitation and decentralized trials. The Davis Phinney Foundation expressed essentially the implementation version of the same argument: what is known scientifically is not necessarily what patients experience. The Plan should therefore finance the bridge from evidence into everyday community life.
The atypical-parkinsonism organizations ensured that the Plan would not quietly become a conventional-PD plan. CurePSP emphasized earlier diagnosis, research-ready registries and biomarker platforms, innovative trials, specialty care and provider education. Mission MSA proposed inclusive/platform trial structures, biospecimen and natural-history infrastructure, elimination of Medicare’s disability waiting period for rapidly progressive atypical disorders, telehealth access and reimbursement for multidisciplinary care. LBDA made an especially important conceptual point: cognition and dementia cannot remain peripheral outcomes in a Parkinson’s plan. Biomarkers and trials should be validated against cognition and function as well as motor outcomes.
The workforce and care-delivery problem
Perhaps the strongest theme of the entire meeting was that scientific knowledge is outrunning the system’s ability to deliver good care. Speakers repeatedly described shortages of movement-disorder specialists, long waits, rural access problems, inadequate training of general neurologists, and the underuse of advanced practice providers.
AMDAPP argued that APPs should augment rather than replace movement-disorder neurologists, with formal education, mentorship and certification. Its larger proposal was continuous multidisciplinary care rather than the current episodic model in which PT, OT, speech therapy or mental-health services are restarted only after deterioration.
Discussion broadened that argument to social workers and care navigators. Members noted the irrationality of treating rehabilitation and psychosocial support as short “episodes” when Parkinson’s is a lifelong progressive condition.
State and community organizations added the implementation perspective: pilot locally, measure quickly, scale nationally. Alabama and Connecticut proposed state needs assessments, stronger referral and navigation systems, rural outreach, multidisciplinary care and formal caregiver strategies. PD Avengers stressed measurable accountability, better payment for comprehensive care, and a national approach to environmental prevention.
Public comments
Public commenters made these abstractions concrete. One woman described living in a prodromal/nonmotor state, including REM sleep behavior disorder, while clinicians failed to recognize the neurological significance of her symptoms. Others raised young-onset disease, medication safety in hospitals and long-term-care facilities, exercise and wellness, research methods, and the need to maintain a relentless focus on disease modification and cure.
Staff summarized the public record as emphasizing urgency and accountability, young-onset and atypical disease, research and innovation, whole-person care, diagnostic delay, specialist access, caregiver and financial burden, and environmental, genetic, and veteran-specific risks.
The emerging architecture of the National Plan
The most consequential conceptual development came from the two subcommittees. The Research and Regulatory Programs Subcommittee proposed organizing the Plan around the patient journey, beginning with risk and prodromal disease and continuing through diagnosis, treatment and advanced disease. Federal activities, evidence gaps, goals and metrics could then be mapped against that journey. The intent is explicitly to avoid producing a disconnected “laundry list” of worthy Parkinson’s initiatives.
The Care, Services and Supports Subcommittee found the same framework useful, provided the “patient journey” explicitly includes families and care partners, rehabilitation, mental and behavioral health, education, telehealth, social services, end-of-life needs and differing trajectories of atypical parkinsonism.
Thus the meeting ended with an emerging philosophy: research and care should not become two separate National Plans. Workforce, diagnosis, research participation, care delivery and outcomes overlap. Both subcommittees will meet monthly, share a common organizing framework, bring in additional experts, and feed their work into two NASEM workshops planned for spring 2027. The Council also recognized important missing voices—notably neurology, physical therapy, nursing and other professional organizations—and intends further targeted outreach.
The August meeting therefore produced few final policy decisions, but considerable convergence about what the eventual Plan must accomplish: more science, better prevention, and substantially better translation of existing knowledge into accessible, longitudinal, measurable care.
